Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
sincerest condolences-
I hope they bury the sob's
cj- my sincerest condolences to you and your family
the halt was @10:24- looks like the trigger was a 15% drop in ask.
29.79 to 25.34
pphmp- cannot short a non-marginable cash security
people that work in crisis management often recommend that 'you get out in front of the oncoming news'.
to your point regarding the 'lack of' and the timing of lly's pr, quite possibly they're simply getting out in front..
If my dashboard which shows icpt short volume yesterday @ 765770 correct- you are certainly correct.
save your 'respect' for those brave enough to build. 'skeptics', by nature are those ill-equipped of both discovery and advancement of concepts, therefore prey on the work of others, you know--- parasites
todays dallas business journal-
The same class of drug used in the experiments is being evaluated in phase 1 and 2 trials for treatment of leukemia and a subtype of lung cancer, Le said. Meanwhile, UT Southwestern is working with a pharmaceutical company to develop a similar BRD4-inhibiting drug to launch a clinical trial for MPNST patients.
http://www.bizjournals.com/dallas/blog/2013/12/ut-southwestern-study-identifies.html?ana=e_du_pub&s=article_du&ed=2013-12-26&page=2
bob more is the higher level
Bob More, Senior Advisor, Bill & Melinda Gates Foundation
the link I sent you is his twitter account with his bio blurb- so in 140 characters or less, consider it the ultimate 'elevator pitch'
BobMore@Bobmorevc
Fan of great banter and inspiring folks. Gates Foundation VC stuff. Be anything but don't be boring.
another-CURRENT development-
'all boats rise with the tide'
http://junotherapeutics.com/
They are technically open market sales conducted by accredited individuals
When our CFO has used the ATM the shares allocated have all been purchased via 'private' transaction. The shares are sold at the market through our MM at 'the days average' price always to an accredited (invited attendee) investor from an investor conference and recorded at the close. As far as information goes, our IR guys are in 'courting' and much more forthwith regarding the company's operation and more willing to share progress of activities. For example- withPeregrine, K&L Gates is on board?doing what? Do you know if they're engaged in M&A activity? Had you come to Peregrine through an investor conference and are considering an investment of$X, chances are either Paul, Jay or Chris in would answer this question. Same with unpublished Class Action knowledge. So even though the ATM allows the MM to 'release to' YOU & I, chances are there're frying bigger fish.
All these, as you see them, 'red flags' and yet you bought the stock certainly lends itself to your admitted state of disorientation. You reference ATM as an issue, have you ever considered that an ATM transaction requires a actual Buyer? Do you have any understanding of the exchange of confidential information required by Peregrine to lure an ATM buyer. There's talk of 'thousands of shares, you realize that means some accredited investor(s) with 'total' access to Company docs made an informed decision to Buy the Stock!
Odd that he ignores your request, maybe he doesn't like marines or perhaps he just feels a little childish!
@BioDueDiligence @chasingthealpha $PPHM: Not only two known red flags, but also an ample supply of waffle words, LOL.
— Roy Friedman (@DewDiligence) November 8, 2013
RT @DewDiligence: $PPHM desperate attempt to have Bavi considered an immunotherapy <- Red flags #1 and 3 in one PR: http://t.co/BGVkhl5GFd
— Andrew G. (@BioDueDiligence) November 8, 2013
good problem to have! I sure you've seen this but maybe some haven't.
http://www.fiercebiotech.com/story/bristol-myers-ax-75-rd-staffers-focus-late-stage-efforts/2013-11-07
TODAY IS A GREAT DAY TO BE AN AMBASSADOR FOR PEREGRINE- a great day to put frustrations aside and recognize that TODAY- ALL THE PRESS IS GOOD- today, instead of bitching about the lack of PR from IR lets promote the great PR we did receive. Its a perfect squeeze day- markets up-news is great - shorts are 'in-the-box' and low on shares- TURN UP THE HEAT-GET ON YOUR TWITTER ACCOUNT AND SPREAD THE WORD
Drop me a note regarding ASM please dkbm3@tx.rr.com
do you have a history of successful prediction’s? Any you’d like to share
regardless of quoted ask, sometimes 'market' will pull downward- the best way to buy 'up' the pps is to always buy with a 'stop' (NOT 'stop limit')and set your buy price- your order will be executed at price only and your order will fill the upward trend
can you share the volume #'s associated with:
with pphm constantly printing more via ATM
also, are you aware of the purchasers of the ATM shares and what are your thoughts if hypothetically Baker Brothers Advisors were one of these purchasers. would the credibility offset the dilution
thanks
I concur
Let's just watch!!!!
Cancer drug shortage and the FDA
http://bit.ly/18QZk4I
CTO
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
September 30, 2013
ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Peregrine Pharmaceuticals, Inc.
File No. 001-32839 - CF#30142
_____________________
Peregrine Pharmaceuticals, Inc. submitted an application under Rule 24b-2
requesting an extension of a previous grant of confidential treatment for information it
excluded from the Exhibits to a Form 10-Q filed on September 9, 2010.
Based on representations by Peregrine Pharmaceuticals, Inc. that this information
qualifies as confidential commercial or financial information under the Freedom of
Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined
not to publicly disclose it. Accordingly, excluded information from the following
exhibits will not be released to the public for the time periods specified:
Exhibit 10.26 through September 9, 2016
Exhibit 10.27 through September 9, 2016
For the Commission, by the Division of Corporation Finance, pursuant to
delegated authority:
Elizabeth M. Murphy
Secretary
Sorry-thanks
Can you share that doc
696-PPHM1319J1.5@0.05
index rebalance?
tomorrow's presentation in boston will be given by Jeffrey T. Hutchins, Ph.D. vice president, preclinical research
thanks- I found it. and also thanks I updated my alerts.
hello- I have fidelity and i'm not familiar with the alert you're referencing:
"Many may not even see this alert... unless you are with Fidelity which sent out the alert tonight"
could you please post the alert?
thanks
just another guy with an oar